Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24

Dallas, Texas–(Newsfile Corp. – June 4, 2024) – Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q1 2024.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• Prexigebersen Phase 2 underway
• Numerous drug candidates in the BPTH pipeline
• $3.5M of funds raised in 2024, giving sufficient liquidity

About Stonegate

Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking, equity research and capital raising for public and private companies.

Contacts:

Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/211731

View more news from Reportable, Inc.

You are receiving this email because you have previously indicated your interest in receiving news for Reportable, Inc.

If you no longer want to receive messages from us, you can click here to unsubscribe.

Anti-Spam Policy | Privacy Policy